O
CRBP icon

OrbiMed’s Corbus Pharmaceuticals CRBP Stock Holding History

OrbiMed’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,667
Closed -$2.94M – 149
2020
Q2 		$2.94M Buy
+11,667
New +$2.36M 0.04% 128

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

OrbiMed's CRBP Position: Q2 2026 in Review

OrbiMed held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 1,737,287 shares worth $16.3M. The position accounts for 0.3% of the portfolio, ranked #72.

OrbiMed first reported a position in CRBP in Q3 2024 and has held it in 8 quarters since. The position peaked at $18.8M in Q3 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • OrbiMed held 1,737,287 shares of Corbus Pharmaceuticals worth $16.3M as of Q2 2026.
  • OrbiMed left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up 0.3% of OrbiMed's portfolio in Q2 2026, its #72 holding.
  • OrbiMed first reported a position in Corbus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • OrbiMed's Corbus Pharmaceuticals position peaked at $18.8M in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.